Age and product dependent vaccine effectiveness against sars-cov-2 infection and hospitalisation among adults in norway: a national cohort study, july-november

HIGHLIGHTS

• who: Jostein Starrfelt from the Department of Infection Control and Preparedness, Norwegian Institute have published the research: Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November, in the Journal: (JOURNAL) of 31/Nov/2021
• what: The aim of this study is to quantify and compare the vaccine effectiveness against infection, disease, and death achieved in the Norwegian population during the Delta epidemic considering time since vaccination, vaccine type, and age groups. The authors show that Spikevax shows a slightly higher vaccine . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.